News and Trends 31 May 2023 Artificial intelligence combats lethal superbug, new antibiotic discovered A new antibiotic called abaucin that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed that AI was able to rapidly screen 7,500 molecules that were found to inhibit the growth of the superbug Acinetobacter baumannii, a task that would be […] May 31, 2023 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 New study reveals Alzheimer’s inflammation protection A possible explanation has been found in a study for why apoE4, the most significant genetic risk factor associated with Alzheimer’s disease, fails to protect the brain from inflammation.Alzheimer’s disease is characterized by the accumulation of plaques of the amyloid-β protein, chronic inflammation and impaired neuronal function in the brain. The most significant genetic risk […] May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Pancreatic cancer microbiome discovery holds treatment hope iNtRON Biotechnology has announced the identification of prophage and (non-) ORF-jamphage from the microbiome frequently observed in long-term pancreatic cancer survivors. The company said the ‘significant identification’ was achieved as part of its ongoing PHAGERIARUS development project conducted by the new drug part of the company. The PHAGERIARUS development project is focused on acquiring bacteriophage-derived […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Potential targets against natural killer/T-cell lymphoma found A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has discovered that a transcription factor, TOX2, was aberrantly increased in patients with natural killer/T-cell lymphoma (NKTL). The increased TOX2 level leads to the growth and spread of NKTL, as well as the overproduction of […] May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Researchers identify gene expression signature to predict progression of type 1 diabetes Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.The study, led by Laura Elo and Riitta Lahesmaa, aimed to identify transcriptional changes associated with disease progression in patients with recent-onset type 1 diabetes. The […] May 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Molecular Partners presenting positive solid tumor data Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 UK invests £650M in life sciences A £650 million ($804 million) war-chest to boost the U.K.’s life sciences sector has been announced. The ‘Life Sci for Growth’ package brings together 10 different policies including £121 million ($150 million) to improve commercial clinical trials to bring new medicines to patients faster, up to £48 million ($59.4 million) of new money for scientific […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 May 2023 Could new Lyme disease tests help to prevent chronic infection? Lyme disease is the most common vector-borne disease in the U.S. – a new CDC estimate suggests that approximately 476,000 Americans are diagnosed with Lyme disease each year – and it is caused by the bacterium Borrelia burgdorferi. It is primarily transmitted to humans through the bite of an infected Ixodes tick; also known as […] May 26, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 26 May 2023Beyond Biotech podcast 47 The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining […] May 26, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 VarmX raises €30M for blood clotting trial VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has successfully raised an additional €30 million ($32.2 million) in a Series B2 financing round. The round was led by Sound Bioventures while the European Innovation Council (EIC) Fund also joined as a new investor. Existing investors EQT Life […] May 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Novartis buys AVROBIO cystinosis gene therapy program for $87.5M AVROBIO, Inc., a clinical-stage gene therapy company working to free people from a lifetime of genetic disease, has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for […] May 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Rocket Pharmaceuticals receives FDA designation for pyruvate kinase deficiency gene therapy Rocket Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the company’s investigational lentiviral-based gene therapy for pyruvate kinase deficiency (PKD). PKD is a rare blood disorder characterized by severe anemia and excessive red blood cell breakdown. RMAT designation was granted based […] May 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email